Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942603 | 0.90 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL642876 | 0.89 | CHRM3 (0.55) | CHRM3 | |
| SCHEMBL942048 | 0.89 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL29949485 | 0.89 | CHRM2 (0.59) | CHRM3 | |
| SCHEMBL643521 | 0.89 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL1302680 | 0.89 | CHRM2 (0.59) | CHRM3 | |
| SCHEMBL942670 | 0.89 | CHRM3 (0.53) | CHRM3 | |
| SCHEMBL643346 | 0.88 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL1304658 | 0.87 | CHRM3 (0.51) | CHRM3 | |
| SCHEMBL1304661 | 0.87 | CHRM3 (0.51) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868175-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-01-11 | — | — | US | claimed |
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-18 | — | — | US | claimed |
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | claimed |
| US-8501776-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110071190-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7868175-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7629336-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-[2-((4-[4-(2-hydroxyethylcarbamoyl)piperidin-1-ylmethyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885 |
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885 |
| US-20110071190-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM1 | CHRM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.